4.4 Article

Assessment of Coronary Atherosclerosis in Patients With Familial Hypercholesterolemia by Coronary Computed Tomography Angiography

期刊

AMERICAN JOURNAL OF CARDIOLOGY
卷 115, 期 6, 页码 724-729

出版社

EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2014.12.034

关键词

-

资金

  1. Banyu Life Science Foundation International
  2. SENSHIN Medical Research Foundation
  3. Uehara Memorial Foundation
  4. Shionogi Co., Ltd.
  5. Daiichi-Sankyo Co., Ltd.
  6. Astellas Pharma Inc.
  7. AstraZeneca K.K.
  8. Kissei Pharmaceutical Co., Ltd.
  9. Bayer Yakuhin, Ltd.
  10. Kyowa Hakim Kirin, Co., Ltd.
  11. MSD K.K.
  12. Sanofi K.K.
  13. Kowa Co., Ltd.
  14. Keiai-Kai Medical Corp.
  15. Biopharm of Japan Co.
  16. Otsuka Pharmaceutical Co., Ltd.
  17. Grants-in-Aid for Scientific Research [26893094] Funding Source: KAKEN

向作者/读者索取更多资源

The aims of this study were (1) to determine whether the accumulation of coronary plaque burden assessed with coronary computed tomography angiography (CCTA) can predict future events and (2) to estimate the onset and progression of coronary atherosclerosis in patients with familial hypercholesterolemia (FH). Consecutive 101 Japanese patients with heterozygous FH (men = 52, mean age 56 +/- 16 years, mean low-density lipoprotein cholesterol 264 +/- 58 mg/dl) who underwent 64-detector row CCTA without known coronary artery disease were retrospectively evaluated by assigning a score (0 to 5) to each of 17 coronary artery segments according to the Society of Cardiovascular Computed Tomography guidelines. Those scores were summed and subsequently natural log transformed. The periods to major adverse cardiac events (MACE) were estimated using multivariable Cox proportional hazards models. During the follow-up period (median 941 days), 21 MACE had occurred. Receiver operating characteristic curve analyses identified a plaque burden score of 3.35 (raw score 28.5) as the optimal cutoff for predicting a worse prognosis. Multivariate Cox regression analysis identified the presence of a plaque score >= 3.35 as a significant independent predictor of MACE (hazard ratio = 3.65; 95% confidence interval 1.32 to 25.84, p <0.05). The regression equations were Y = 0.68X - 15.6 (r = 0.54, p <0.05) in male and Y = 0.74X - 24.8 (r = 0.69, p <0.05) in female patients with heterozygous FH. In conclusion, coronary plaque burden identified in a noninvasive, quantitative manner was significantly associated with future coronary events in Japanese patients with heterozygous FH and that coronary atherosclerosis may start to develop, on average, at age 23 and 34 years in male and female patients with heterozygous FH, respectively. (C) 2015 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据